An Open-Label, Single-arm Study to Evaluate the Safety and Efficacy of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 8
- 主要终点
- Overall Response Rate (ORR), Central Independent Review Assessed by RECIST v1.1
研究概览
简要总结
This was a single-arm, open label, multicenter phase II, study of dabrafenib in combination with trametinib in Chinese participants with BRAF V600E mutation positive, stage IV NSCLC (American joint committee on cancer staging 8th edition). Approximately 40 Chinese adults were to be enrolled in this study. Participants were to be treated with dabrafenib in combination with trametinib until disease progression, start of a new anti-neoplastic therapy, unacceptable toxicity, pregnancy, withdrawal of consent, lost to follow-up, physician's decision, death, or if study be terminated by the sponsor. The general study design was discussed and agreed with China National Medical Products Administration and was based on a similar design used in the global pivotal phase II study (Study 113928 / NCT01336634).
详细描述
This is a single arm, open label, multicenter phase II study evaluating the efficacy and safety of dabrafenib in combination with trametinib in Chinese participant with BRAF V600E mutation positive AJCC v8 stage IV Non-Small Cell Lung Cancer.
Participants with stage IV BRAF V600E mutant Non-Small Cell Lung Cancer confirmed by local qualified assay (approved by China health authorities) will be enrolled in this study. Central confirmation testing for BRAF V600E will be performed. This study will enroll participants:
- who have not received any prior systemic anti-cancer therapy for metastatic disease (i.e. dabrafenib/trametinib will be the 1st line treatment for metastatic disease)
- who have relapsed or progressed on at least one prior platinum based chemotherapy prior to enrollment but cannot have received more than 3 prior systemic therapies for metastatic disease (i.e. dabrafenib/trametinib will be no less than second line treatment for metastatic disease).
All participants must not have been previously exposed to a BRAF or MEK inhibitor. Participants will receive the recommended dose of both drugs (dabrafenib 150 mg twice daily and trametinib 2 mg once daily).
The primary endpoint for the study is Overall Response Rate, as determined by central independent review, using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of Stage IV NSCLC (according to AJCC 8th edition) that is BRAF V600E mutation-positive by local test result from a qualified assay (NMPA and/or MOH-approved)
- •Previously treated or untreated for metastatic NSCLC:
- •Participants previously treated should have received no more than 3 prior systemic therapies for metastatic disease, with at least one prior platinum based chemotherapy, and should have documented disease progression on a prior treatment regimen (i.e. RECIST 1.1)
- •Participants who have received prior therapy with checkpoint inhibitor therapy (i.e. anti-PD-1/PD-L1) must have had objective evidence of disease progression (i.e. RECIST v1.1) while on or after this therapy prior to enrollment.
- •Participants with EGFR or ALK mutation who have previously received therapy with EGFR or ALK inhibitor(s) respectively are eligible
- •Measurable disease per RECIST v1.1
- •Anticipated life expectancy of at least 3 months
- •ECOG performance status ≤
- •Adequate bone marrow and organ function as defined by the following laboratory values without continuous supportive treatment (such as blood transfusion, coagulation factors and/or platelet infusion, or red/white blood cell growth factor administration) as assessed by local laboratory for eligibility: Hemoglobin ≥ 9 g/dL; Absolute neutrophil count ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L; PT/INR and PTT ≤ 1.5 x ULN; Serum creatinine < 1.5 mg/dL; Total bilirubin ≤ 1.5 × ULN (upper limit of normal) except for participants with Gilbert's syndrome who may only be included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN, except for participant with liver metastasis, who may only be included if AST/ALT ≤ 5.0 × ULN Albumin ≥ 2.5 g/dL
- •Left ventricular ejection fraction (LVEF) ≥ lower limit of institutional normal (LLN) as assessed by ECHO or MUGA scan
排除标准
- •Participants with brain or leptomeningeal metastases are excluded if their these metastases are: symptomatic or treated but not clinically and radiographically stable 3 weeks after local therapy or asymptomatic and untreated but >1 cm in the longest dimension
- •Previous treatment with a BRAF inhibitor or a MEK inhibitor
- •All prior anti-cancer treatment-related toxicities must be Grade 2 or less according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.03; NCI, 2009) at the time of enrollment
- •Prior anti-cancer treatment within the last 2 weeks, and prior treatment with immune checkpoint inhibitors within 4 weeks preceding the first dose of the study treatment.
- •Current use of a prohibited medication
- •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO).
- •Participants with known history for testing positive for Human Immunodeficiency Virus (HIV)
- •History of another malignancy <3 years prior to starting study treatment or any malignancy with confirmed activating RAS-mutation.
- •Cardiac or cardiac repolarization abnormality
- •A history or current evidence/risk of retinal vein occlusion (RVO) or serous retinopathy
- •History or current interstitial lung disease or non-infectious pneumonitis
- •Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that, in the opinion of the investigator, could interfere with the participant's safety, obtaining informed consent, or compliance with study procedures
- •Pregnant or nursing (lactating) women.
- •Sexually active males (including those that have had a vasectomy) must use a condom during intercourse and should not father a child during this period. The amount of time a patient must use a condom for 16 weeks post treatment discontinuation
- •Participants with active Hepatitis B infection (HbsAg positive)
- •Participants with positive test for hepatitis C ribonucleic acid (HCV RNA)
- •Concurrent participation in other clinical trials using experimental therapies
研究组 & 干预措施
Dabrafenib in combination with trametinib
Dabrafenib 150 mg twice daily, trametinib 2 mg once daily
干预措施: Dabrafenib (Drug)
Dabrafenib in combination with trametinib
Dabrafenib 150 mg twice daily, trametinib 2 mg once daily
干预措施: Trametinib (Drug)
结局指标
主要结局
Overall Response Rate (ORR), Central Independent Review Assessed by RECIST v1.1
时间窗: From baseline until disease progression, death, lost to follow-up or withdrawal of consent, whichever occurs first, assessed up to approximately 50 months from treatment initiation
Overall Response Rate (ORR) was defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR), as per central independent review assessment and according to RECIST 1.1.
次要结局
- Overall Response Rate (ORR), Investigator Assessed by RECIST v1.1(From baseline until disease progression, death, lost to follow-up or withdrawal of consent, whichever occurs first, assessed up to approximately 50 months from treatment initiation)
- Progression Free Survival (PFS), Investigator Assessed by RECIST v1.1(From baseline until disease progression or death due to any cause, whichever occurs first, assessed up to approximately 50 months from treatment initiation)
- Duration of Response (DoR), Investigator Assessed by RECIST v1.1(From first documented response until first documented progression or death due to any cause, whichever occurs first, assessed up to approximately 50 months from treatment initiation)
- Overall Survival (OS)(From baseline until death due to any cause, assessed up to approximately 50 months from treatment initiation)
- Trough Concentration of Dabrafenib(Pre-dose sample at visits week 3, 6 and 12)
- Trough Concentration of Dabrafenib Metabolites (Hydroxy-dabrafenib, and Desmethyl-dabrafenib)(Pre-dose sample at visits week 3, 6 and 12)
- Trough Concentration of Trametinib(Pre-dose sample at visits week 3, 6 and 12)
- Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L)(Baseline (BL), Week 12, End of Treatment (up to approximately 50 months after treatment initiation))
- Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale(Baseline (BL), Week 12, End of Treatment (up to approximately 50 months after treatment initiation))
- Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13)(Baseline (BL), Week 12, End of Treatment (up to approximately 50 months after treatment initiation))
- Percentage of Participants With Adverse Events (AEs)(From baseline until end of study, assessed up to approximately 50 months)